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In vivo action of IL-27: reciprocal regulation of Th17
and Treg cells in collagen-induced arthritis
Su-Jin Moon1,5, Jin-Sil Park2,5, Yu-Jung Heo2, Chang-Min Kang2, Eun-Kyung Kim2, Mi-Ae Lim2,
Jun-Geol Ryu2, Seong Jeong Park3, Kyung Su Park2,4, Young-Chul Sung3, Sung-Hwan Park2,4, Ho-Youn Kim2,4,
Jun-Ki Min1,6 and Mi-La Cho2,6
Interleukin (IL)-27 is a novel cytokine of the IL-6/IL-12 family that has been reported to be involved in the pathogenesis of
autoimmune diseases and has a pivotal role as both a pro- and anti-inflammatory cytokine. We investigated the in vivo effects
of IL-27 on arthritis severity in a murine collagen-induced arthritis (CIA) model and its mechanism of action regarding control
of regulatory T (Tregs) and IL-17-producing T helper 17 (Th17) cells. IL-27-Fc-treated CIA mice showed a lower severity of
arthritis. IL-17 expression in the spleens was significantly decreased in IL-27-Fc-treated CIA mice compared with that in the
CIA model. The Th17 population was decreased in the spleens of IL-27-Fc-treated CIA mice, whereas the CD4þCD25þFoxp3þ
Treg population increased. In vitro studies revealed that IL-27 inhibited IL-17 production in murine CD4þ T cells, and the
effect was associated with retinoic acid-related orphan receptor cT and signal transducer and activator of transcription 3
inhibition. In contrast, fluorescein isothiocyanate-labeled forkhead box P3 (Foxp3) and IL-10 were profoundly augmented by
IL-27 treatment. Regarding the suppressive capacity of Treg cells, the proportions of CTLA-4þ (cytotoxic T-lymphocyte antigen
4), PD-1þ (programmed cell death protein 1) and GITRþ (glucocorticoid-induced tumor necrosis factor receptor) Tregs
increased in the spleens of IL-27-Fc-treated CIA mice. Furthermore, in vitro differentiated Treg cells with IL-27 exerted a more
suppressive capacity on T-cell proliferation. We found that IL-27 acts as a reciprocal regulator of the Th17 and Treg populations
in CD4þ cells isolated from healthy human peripheral blood mononuclear cells (PBMCs), as well as from humans with
rheumatoid arthritis (RA) PBMCs. Our study suggests that IL-27 has the potential to ameliorate overwhelming inflammation in
patients with RA through a reciprocal regulation of Th17 and Treg cells.
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INTRODUCTION
Interleukin (IL)-27 is a member of a heterodimeric cytokine
produced by antigen-presenting cells (APCs), including mono-
cytes and dendritic cells. It belongs to the IL-12 cytokine family,
which also includes IL-23 and IL-35.1 IL-27 is composed of the
Epstein–Barr virus-induced gene 3 (EBI3) and p28 subunits,
and has been demonstrated to have a pivotal role as both a
pro- and anti-inflammatory cytokine.2 A recent report by
Wojno et al.3 showed that IL-27 transgenic mice exhibited a
systemic inflammatory condition accompanied by an increased
percentage of activated T cells and an elevated interferon
(IFN)-g level. In that study, IL-27 transgenic mice lacked
regulatory T (Treg) cells in lymphoid organs, suggesting
that the inappropriate inflammation was caused by a Treg
deficiency. Regarding the T helper type 1 (Th1) cells, IL-27
is thought to mediate the proinflammatory response by
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modulating the early stage of Th1 cell differentiation via
induction of the IL-12 receptor b2 expression.4 On
the contrary, IL-27R/ CD4þ T cells produce more IL-2
than wild-type cells during Th1 differentiation, suggesting that
IL-27 has anti-inflammatory properties.5 Taken together, the
in vivo and in vitro consequences of the response of immune
cells to IL-27 appear to be a complicated and a complex
problem.
Rheumatoid arthritis (RA) is a systemic inflammatory
disease characterized by hyperplasia of the synovial tissue and
progressive destruction of joint structure (cartilage, bone and
ligament). If inflammation is uncontrolled, the chronic pro-
gression of RA could result in complete ankylosis and
subsequent loss of joint function. The pathogenesis of RA is
a complex process mediated by an interdependent network of
cytokines, prostanoids and proteolytic enzymes.6 Represen-
tative proinflammatory cytokines include tumor necrosis
factor, IL-1 and IL-6, the levels of which are increased in
patients with RA compared with other forms of arthritis.7,8
However, relatively few reports have investigated populations or
the biological function of the anti-inflammatory cytokines such
as IL-27, until now. One recent study by Niedbala et al.9
determined that IL-27 is expressed by the synovial tissues in
RA, and short-term administration of IL-27 at the onset of
arthritis significantly attenuated the severity of the disease using
a murine model of collagen-induced arthritis (CIA), suggesting
protective roles for IL-27 in the pathogenesis of RA.9 However,
other studies have disagreed with the in vitro function of IL-27
when studied in humans. For instance, Wong et al.10
demonstrated that high concentrations of IL-27 induced the
production of IL-6 and inflammatory chemokines from
fibroblast-like synoviocytes of RA.
Several in vivo animal models and in vitro human studies
have suggested that IL-17-producing T helper (Th17) cells can
be considered a decisive mediator of RA with respect to joint
inflammation and enhanced osteoclastogenesis.11,12 Along with
Th17, Treg cells have been highlighted in both the pathogenesis
of RA as well as in therapeutic strategies for the treatment of
RA. Treg cells are pivotal immune cells and are a distinct
regulatory lymphocyte that functions through the suppression
of harmful autoimmune T cells in the periphery.13
We recently investigated the effects of IL-27 in a murine model
and demonstrated that IL-27-Fc-injected CIA showed lower
arthritis indices and fewer osteoclastogenesis.14 Furthermore,
the in vivo effect of IL-27 in the aspect of modulation of Th17
and Treg populations was examined in our present study. To
the extent of our knowledge, this is the first study that has s
hown the anti-inflammatory property of IL-27 through
reciprocal regulation of Th17 and Treg populations, which may
contribute to its antiarthritic effects.
MATERIALS AND METHODS
Animals
Four- to 6-week-old male DBA/1J mice were purchased from SLC
(Shizuoka, Japan) and were housed in polycarbonate cages and fed
with standard mouse chow (Ralston Purina, St Louis, MO, USA) and
water ad libitum. To confirm the in vivo effect of IL-27 in a CIA
model, the mice were randomized into two groups of six animals
each. All experimental procedures were examined and approved by
the Animal Research Ethics Committee of the Catholic University of
Korea.
Plasmid construction
Codon-optimized mouse IL-27p28 (GenBank: 145636), IL-27EBI3
(GenBank: 015766) and the Fc region of non-cytolytic mIgG2a15
genes were synthesized using codons for mammalian cell expression
by GeneScript (Piscataway, NJ, USA) and cloned into the pUC57
plasmid. Codon-optimized mouse IL-27p28 (mp28co), the internal
ribosomal entry site (IRES) of the encephalomyocarditis virus, mouse
IL-27EBI3 (mEBI3co) and non-cytolytic Fc (mFcm) were linked in a
tandem, unidirectional arrangement. The expression cassettes of
mp28co-IRES-mEBI3co and mp28co-IRES-mEBI3co-mFcm were inserted
into the pGX10 vector,16 using the EcoRV/NcoI or EcoRV/NotI
restriction enzyme sites to generate the pGX10-mp28co-IRES-mEBI3co
and pGX10-mp28co-IRES-EBI3co-mFcm constructs.
Induction of CIA and administration of IL-27
To induce CIA in DBA1/J mice, type II collagen (CII) was dissolved
overnight in 0.1 N acetic acid (4 mg ml1) with gentle rotation at 4 1C.
The mice were injected intradermally at the base of the tail with
100mg CII emulsified 1:1 (w v1) in complete Freund’s adjuvant
(Chondrex, Redmond, WA, USA). The hydrodynamic gene delivery
via tail vein injection is a highly efficient and simple procedure to
deliver plasmid DNA into small animals. Eight days after the CII
immunization, the mice were rapidly injected intravenously with
100mg IL-27-Fc in 2 ml saline within 5 s. To enhance the efficiency of
gene therapy in vivo, subsequent intramuscular electrical stimulation
(electroporation) was used. Intramuscular electroporation gene
transfer is a highly effective method for increasing gene expression
by creating transient pores in the cell membrane through which the
plasmids can enter the cells.17 Eight days after the hydrodynamic
injection, the same mice were injected intramuscularly with 100mg
IL-27-Fc in the left leg by electroporation. The intramuscular
injection was performed with a 31-G insulin syringe. After 2 days,
they were injected intramuscularly with 100mg IL-27-Fc in the right
leg by electroporation.
Immunohistochemical analysis of IL-27
Five-micrometer sections of RA and synovium were fixed in 4%
paraformaldehyde, decalcified in ethylenediaminetetraacetic acid
-containing bone decalcifier, embedded in paraffin and sectioned.
The tissues were incubated with the primary antibody to IL-27 (R&D
Systems, Minneapolis, MN, USA) overnight at 4 1C. The tissues were
then incubated with a biotinylated secondary antibody and a
streptavidin–peroxidase complex for 1 h.
Confocal microscopy of immunostaining
Spleen tissues were snap frozen in liquid nitrogen and stored at
70 1C. Tissue sections (7mm) of the spleens were fixed in acetone
and stained for Treg cell marker stain using phycoerythrin (PE)- or
fluorescein isothiocyanate (FITC)-labeled forkhead box P3 (Foxp3),
peridinin chlorophyll-labeled anti-CD4, APC-labeled anti-CD25,
FITC-labeled programmed cell death protein 1 (PD-1), biotin anti-
mouse glucocorticoid-induced tumor necrosis factor receptor (GITR)
(all from eBioscience, San Diego, CA, USA), PE-labeled cytotoxic
T-lymphocyte antigen 4 (CTLA-4) and second streptavidin-FITC
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(both from BD Bioscience, Oxford, UK) antibody. To stain the Th17
marker, PE-labeled IL-17 antibody (eBioscience) and FITC-labeled
anti-CD4 antibody were used. After incubation overnight at 4 1C, the
stained sections were analyzed using a confocal microscopy system
(LSM 510 Meta, Carl Zeiss, Oberkochen, DE, USA). Positive
cells were enumerated visually at higher magnification by four
individuals.
Murine cell preparation and culture
The C57BL/6 mouse spleens were collected for cell preparation and
washed two times with phosphate-buffered saline. The spleens were
minced and the red blood cells were lysed with 0.83% ammonium
chloride. The cells were filtered through a cell strainer and centrifuged
at 1300 r.p.m. at 4 1C for 5 min. To purify the splenic CD4þ T cells,
the splenocytes were incubated with CD4-coated magnetic beads and
isolated using magnetic-activated cell sorting separation columns
(Miltenyi Biotec, Bergisch Gladbach, Germany). CD4þ T cells were
stimulated with various stimuli such as anti-CD3 (0.5mg ml1; BD
Bioscience, San Diego, CA, USA), IL-23 (5 ng ml1; R&D Systems) or
IL-27 (10 ng ml1; R&D Systems). To establish the Treg-polarizing
condition, the CD4þ T cells were stimulated with plate-bound anti-
CD3 (0.5mg ml1), anti-CD28 (0.5mg ml1), anti-IFN-g (2mg ml1),
anti-IL-4 (2mg ml1) and transforming growth factor-b (TGF-b)
(5 ng ml1) for 3 days.
Human cell preparation and culture
Peripheral blood mononuclear cells (PBMCs) obtained from healthy
volunteers or RA patients were isolated from buffy coats using Ficoll-
Hypaque (Amersham Biosciences, Pittsburg, PA, USA) and density
gradient centrifugation. CD4þ T cells were isolated using a CD4þ
T-cell isolation kit (Miltenyi Biotec) according to the manufacturer’s
instructions. CD4þ T cells were plated at 1 106 cells per well in a
24-well plate and then stimulated with plate-bound anti-CD3
(0.5mg ml1) and anti-CD28 (0.5mg ml1) antibodies (both from
BD Bioscience) with no cytokine added in the presence or absence of
IL-27 (10 ng ml1) for 3 days. To establish the Th17-polarizing
condition, the CD4þ T cells were stimulated with plate-bound
anti-CD3 (0.5mg ml1), anti-CD28 (0.5mg ml1), anti-IFN-g
(2mg ml1), anti-IL-4 (2mg ml1), IL-1b (5 ng ml1) and IL-6
(20 ng ml1) for 3 days. All cytokines were from R&D Systems,
except for TGF-b (Peprotech, Rocky Hill, NJ, USA).
Intracellular staining and flow cytometry
Intracellular staining was performed as described.18 The following
antibodies were used for intracellular staining of the mouse cells: anti-
CD4- peridinin chlorophyll, anti-CD25-APC, anti-PD-1-FITC, anti-
GITR-biotin, anti-IL-17A-FITC, anti-Foxp3-PE or FITC (all from
eBioscience), streptavidin-FITC and anti-CTLA4-PE (BD Bioscience).
The following antibodies were used for intracellular staining of
human cells: anti-CD4-PEcy7, anti-CD25-APC, anti-IL-10-PE (BD
Bioscience), anti-Foxp3-FITC and anti-IL-17A-PE (eBioscience).
Mixed lymphocyte reaction
To examine the suppressive activity of Treg cells following IL-27
stimulation, CD4þCD25þ (peridinin chlorophyll-labeled anti-CD4
and APC-labeled anti-CD25, eBioscience) T cells were sorted (Dako-
Cytomation MoFlo, Ely, UK) from CD4þ T cells that were stimulated
with or without IL-27 (10 ng ml1) under Treg-polarizing conditions
for 3 days. Sorted CD4þCD25þ cells were cocultured with T cells
and irradiated APC (7500 cGy) at a 0.2:1:1 ratio in the presence of
anti-CD3 (0.5mg ml1). During the last 16–18 h, cells were pulsed
with 1mCi of [3H]thymidine (GE Healthcare, Little Chalfont, UK) per
well. The incorporation of [3H]thymidine was determined using a
Betaplate scintillation counter (Perkin-Elmer, Wellesley, MA, USA).
Real-time PCR
Gene expression was analyzed by real-time quantitative PCR. Total
RNA was prepared from 1 106 cells and was extracted using TRIzol
reagent (Molecular Research Center, Cincinnati, OH, USA). Two
micrograms of total RNA were reverse transcribed using the Super-
script Reverse Transcription system (Takara, Shiga, Japan). The levels
of mRNA expression were estimated using real-time quantitative PCR
with LightCycler FastStart DNA Master SYBR Green I (Takara)
according to the manufacturer’s instructions. The following primers
were used for mouse samples: IL-17, 50-CCTCAAAGCTCAGCGTGT
CC-30 (sense) and 50-GAGCTCACTTTTGCGCCAAG-30 (antisense);
retinoic acid-related orphan receptor gT (RORgT), 50-TGTCCTGGG
CTACCCTACTG-30 (sense) and 50-GTGCAGGAGTAGGCCACATT-30
(antisense); signal transducer and activator of transcription 3
(STAT3), 50-GACCCGCCAACAAATTAAGA-30 (sense) and 50-TCGT
GGTAAACTGGACACCA-30 (antisense); Foxp3, 50-GGCCCTTCTCC
AGGACAGA-30 (sense) and 50-GCTGATCATGGCTGGGTTGT-30
(antisense); IFN-g, 50-AGACATTCACAATTGATTTTATTCTTAC-30
(sense) and 50-CCTTCCTGTAGGGTATTATTATACG-30 (antisense);
IL-10, 50-TCCTTAATGCAGTTTAAGGGTT-30 (sense) and 50-GACAC
CTTGGTCGAGCTTATT-30 (antisense); and b-actin, 50-GTACGACC
AGAGGCATACAGG-30 (sense), 50-GATGACGATATCGCTGCGCTG-
30 (antisense). The amplification reactions, data acquisition and
analyses were performed using the LightCycler Real-Time PCR system
(Roche Diagnostics, Mannheim, Germany), and the relative levels of
gene expression were normalized against b-actin.
Determination of cytokine concentrations in culture
supernatants
The amounts of IL-17 and IL-10 for mouse samples and IL-17, IFN-g
and IL-10 for human samples in the culture supernatants were
measured by sandwich enzyme-linked immunosorbent assay (ELISA)
(R&D Systems). The absorbance was determined with an ELISA
microplate reader at 405 nm (Molecular Devices, Sunnyvale,
CA, USA).
Statistical analysis
Data are presented as the mean±standard deviation (s.d.). The
Mann–Whitney U-test was used for comparing values between two
groups. One-way analysis of variance followed by Bonferroni’s post
hoc test was used to compare the differences between three or more
groups. To assess the Gaussian distribution and the equality of
variance, the Shapiro–Wilk test and Levene test were used, respec-
tively. The program used for the statistical analysis was the SPSS
statistical software package, standard version 16.0 (SPSS, Chicago, IL,
USA). P-values o0.05 (two-tailed) were considered significant.
RESULTS
The regulatory effect of IL-27 on the Th17/Treg population
during CIA development
To determine whether IL-27 modulates disease severity in vivo,
IL-27-Fc was administered by hydrodynamic injection into
mice 8 days after CII immunization. Treatment with IL-27-Fc
significantly ameliorated arthritis severity and incidence
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(Figure 1a). Therefore, we determined whether the protective
effect of IL-27 in CIA occurs via modulation of the Th17 and
Treg populations. CD4þ T cells were isolated from the spleens
of CIA- and IL-27-Fc-treated CIA animals on week 4 after
primary CII immunization. The results showed that the
population of IL-17-expressing splenocytes decreased in IL-
27-Fc-treated CIA mice compared with that of CIA, whereas
the proportion of IFN-g- and IL-10-expressing splenocytes did
not differ between the two groups (Figure 1b). Flow cyto-
metric analysis identified a modest expansion of CD4þ
CD25þFoxp3þ Treg cells in the spleens of IL-27-Fc-treated
CIA animals (7.08% versus 8.39% in CIA- versus IL-27-Fc-
treated CIA, respectively) (Figure 1c). Confocal microscopy
illustrated significantly decreased CD4þ IL-17þ cell popula-
tions (Th17 cells) in the spleens of IL-27-Fc-treated CIA
animals, whereas the CD4þCD25þFoxp3þ cell population
(Treg cells) expanded (Figure 1d). The results showed that
IL-27 administration in CIA animals has an anti-inflammatory
role through Th17 inhibition and the reciprocal induction of
Treg cells.
In vitro effect of IL-27 on IL-17, IFN-g, Foxp3 and IL-10 in
murine CD4þ T cells
To identify the mechanism of IL-27 in autoimmune arthritis
mice, in vitro experiments were conducted to verify the
changes in cytokines and transcriptional factors that are
implicated in Th17 and Treg cells. CD4þ T cells were isolated
from normal C57BL/6 mice and then stimulated with anti-
CD3 in the presence or absence of IL-23 or IL-27 for 3 days.
IL-23 is known to contribute to Th17 differentiation. As we
Figure 1 In vivo therapeutic effects of interelukin (IL)-27 via reciprocal regulation of T helper 17 (Th17) and Treg cells on collagen-
induced arthritis (CIA) development. Eight days after CIA induction, IL-27-Fc was administered by hydrodynamic intravenous injection
in IL-27-Fc-treated CIA animals. Eight and 10 days thereafter, the mice received two additional injections of IL-27-Fc in the muscles
of both thighs by electroporation. (a) The clinical score and arthritis incidence rate of disease are shown for both CIA and
IL-27-Fc-treated CIA mice over time. Data are representative of two independent experiments with six vanished animals per group
(error bar, s.d.). (b) Mice were killed on day 28 after CIA induction, and the expression of IL-17, interferon (IFN)-g and IL-10 was
analyzed on the splenocytes from each group using flow cytometry. The representative flow cytometric dot plots for each group are shown.
(c) The populations of CD4þCD25þFoxp3þ cells were analyzed by flow cytometry of the isolated splenocytes of each group.
(d) Expression of CD4þ IL-17þ or CD4þCD25þFoxp3þ cells in the spleens of CIA and IL-27-Fc-treated CIA mice was analyzed
by immunostaining and confocal microscopy. The data are expressed as the mean±s.d. (error bar) for six animals per group.
Original magnification, 400. *Po0.05, **Po0.01, ***Po0.001 compared with CIA. Fosxp3, fluorescein isothiocyanate-labeled
forkhead box P3.
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expected, the mRNA expression of Th17-associated molecules
increased following IL-23 treatment. Interestingly, the
increased mRNA levels of IL-17, RORgT and STAT3 following
IL-23 stimulation were diminished by IL-27 treatment, sup-
porting the anti-inflammatory effect of IL-27 through Th17
inhibition shown in vivo above (Figure 2a). On the contrary,
the mRNA level of IFN-g profoundly increased following IL-27
treatment but not after IL-23 treatment. IL-17 concentrations
measured in the culture supernatant showed that the increased
level of IL-17 following IL-23 treatment had vanished follow-
ing IL-27 treatment.
Foxp3 is a key transcriptional factor known to be involved
in Treg differentiation. Isolated murine CD4þ T cells were
stimulated with IL-27 for 3 days, and the mRNA levels were
determined by real-time PCR. The results show that the
mRNA levels of Foxp3 and IL-10 were significantly increased
following IL-27 treatment compared with those without. The
level of IL-10 as a Treg-associated cytokine was also measured
in the culture supernatant. The result showed that the IL-27
treatment increased IL-10 concentrations compared with those
without (Figure 2b). The cell viability did not differ between
the groups (data not shown).
Characterization of the suppressive functions of Treg cells in
IL-27-Fc-treated CIA
CTLA-4 and PD-1 have been revealed to augment the
suppressive capacity of Treg cells on the activation of effector
T cells.19,20 In addition, the expression of GITR on Tregs
increases upon its activation compared with that of naive
Treg.21 To ascertain whether IL-27-Fc treatment in arthritic
mice influenced molecules that are implicated in the
suppressive function of Tregs, the proportions of CTLA4þ ,
PD-1þ and GITRþ cells among the CD4þCD25þFoxp3þ
Treg cells gated from each group of mice were identified using
fluorescence-activated cell sorter (Figure 3a). The numerical
analysis of CD4þCD25þFoxp3þCTLA4þ , CD4þCD25þ
Foxp3þPD-1þ and CD4þCD25þFoxp3þGITRþ cells in
the field was performed by confocal microscopy (Figure 3c).
Figure 2 In vitro regulatory effects of interleukin (IL)-27. (a) Splenic CD4þ T cells were isolated from normal C57BL/6 mice and then
stimulated with anti-CD3 (0.5mgml1) in the presence or absence of IL-23 (5ngml1) or IL-27 (10ngml1) for 3 days. Expression of
mRNA levels of IL-17, retinoic acid-related orphan receptor gT (RORgT), signal transducer and activator of transcription 3 (STAT3) and
interferon (IFN)-g was analyzed by real-time polymerase chain reaction (PCR), and the IL-17 concentration of the culture supernatant was
measured by enzyme-linked immunosorbent assay (ELISA). *Po0.05, **Po0.01, ***Po0.001 compared with that in the absence of
IL-27. (b) Splenic CD4þ T cells isolated from normal C57BL/6 mice were cultured in the presence or absence of IL-27 for 3 days. The
mRNA expression of fluorescein isothiocyanate-labeled forkhead box P3 (Foxp3) and IL-10 was determined by real-time PCR, and the
IL-10 concentration in the culture supernatant was measured by ELISA. The data are expressed as the mean±s.d. (error bar) for three
independent experiments. *Po0.05, **Po0.01 compared with those without.
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Interestingly, the proportion of PD-1-, GITR- or CTLA4-
positive cells among the Treg cells increased in the IL-27-Fc-
treated CIA spleen compared with that in the CIA mice.
Among the three molecules, the most profound difference
between the two groups was in CTLA-4. In addition, we
attempted to verify the effects of IL-27 on the suppressive
capacity of Treg cells. Therefore, murine CD4þ T cells were
cultured for 3 days under Treg-polarizing conditions in the
presence or absence of IL-27 (10 ng ml1). Then, sorted
CD4þCD25þ cells were cocultured with murine CD4þ
T cells and irradiated APCs in the presence of anti-CD3 for
3 days. Although the difference was marginal, IL-27 treatment
tended to increase the suppressive activity of Tregs on T-cell
proliferation (Figure 3b).
These results suggested that Treg cells from IL-27-Fc-treated
CIA mice may exert more suppressive activity, which may
explain the anti-inflammatory effect of IL-27 shown in vivo.
Furthermore, to ascertain whether the enhanced expressions of
CTLA-4, PD-1 and GITR following IL-27 treatment were
limited to Treg cells, and the levels of the three molecules on
effector T cells (CD4þCD62LlowCD44high) were determined
by fluorescence-activated cell sorter. Contrary to Treg cells, the
Figure 3 Changes in CTLA-4þ (cytotoxic T-lymphocyte antigen 4), PD-1þ (programmed cell death protein 1) or GITRþ (glucocorticoid-
induced tumor necrosis factor receptor) regulatory T (Treg) populations in the spleen of interleukin (IL)-27-Fc-treated collagen-induced
arthritis (CIA). (a) The proportion of CTLA-4þ , PD-1þ or GITRþ Treg cells was assessed ex vivo by intracellular flow cytometry.
CD4þCD25þFoxp3þ cells were gated from splenocytes of each group of mice. Then, the expression of CTLA-4, PD-1 or GITR among
these cells was identified by flow cytometric analysis. Data shown in left panel are representative of three results. (b) CD4þCD25þ
regulatory T cells induced under Treg-polarizing condition with or without IL-27 were cocultured with murine CD4þ T cells and irradiated
antigen-presenting cells (APCs) (7500cGy) for 3 days. T-cell proliferation was determined using the [3H]thymidine incorporation assay.
Treg cells with IL-27 stimulation exerted more suppressive properties. (c) Spleens from mice of each group were examined by confocal
microscopy for staining with mouse antibodies against CD4 (white), CD25 (blue), fluorescein isothiocyanate-labeled forkhead box P3
(Foxp3) (red), PD-1 (green), GITR (green) and CTLA-4 (green) (left panel) (original magnification at 400). The graph (right panel)
represents the number of PD-1þ , GITRþ or CTLA4þ Treg (represented by CD4þCD25þFoxp3þ ) cells that were found in the spleens of
CIA- or IL-27-Fc-treated CIA. The number of PD-1þ , GITRþ and CTLA4þ Treg cells increased in the spleens of IL-27-Fc-treated CIA
mice compared with that of CIA. The data are expressed as the mean±s.d. (error bar) for six mice in each group. (d) CTLA-4-, PD-1- and
the GITR-expressing cell populations among effector T cells (CD4þCD62LlowCD44high) were analyzed by flow cytometric analysis. In
contrast to Treg cells, CTLA-4, PD-1 and GITR expression was similar between effector T cells isolated from each group. SSC, side scatter
channel.
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proportion of the molecules on effector T cells did not differ
between the two groups (Figure 3d). Taken together, IL-27
treatment in CIA animals may augment Treg function through
CTLA-4 induction. Furthermore, the effect was limited to the
Treg population.
IL-27 as a reciprocal regulator of human Th17 and Treg
differentiation
CD4þ T cells were isolated from human PBMCs of healthy
volunteers and then stimulated with anti-CD3 plus anti-CD28
stimulation with no cytokine added (Th0 condition) or under
Th17-polarizing condition in the presence or absence of IL-27
(10 ng ml1) for 3 days. Flow cytometric analysis using
intracellular staining was used to analyze the Th17 and Treg
populations. In the Th0 condition, IL-27 treatment modestly
decreased the CD4þ IL-17þ (Th17) cell population, whereas
there was no significant change in the population of CD4þ
IFN-gþ cells. However, the proportion of Th17 cells decreased
following IL-27 treatment, whereas the CD4þ IFN-gþ T-cell
population expanded under the Th17-polarizing condition
(Figure 4a).
Regarding the Treg cells, IL-27 treatment markedly increased
the CD4þCD25þFoxp3þ Treg proportion under the Th17-
polarizing condition (Figure 4b). Furthermore, the IL-17
concentration in the culture supernatant was measured by
ELISA. IL-27 treatment under Th17-polarizing conditions, not
under the Th0 condition, significantly inhibited IL-17 levels in
a dose-dependent manner. Reciprocally, IL-10 production
in CD4þ T cells in Th17-polarizing conditions tended to
increase following IL-27 treatment, although the difference was
not statistically significant. The IFN-g level did not change
following IL-27 treatment in either condition (Figure 4c).
In vitro effect of IL-27 on Th17 and Treg populations in RA
patients and the expression of IL-27 in the RA synovium
We attempted to ascertain the effects of IL-27 on Th17
and Treg differentiation in RA CD4þ T cells. CD4þ T
cells isolated from the PBMCs of RA patients were cultured
in the presence of anti-CD3 plus anti-CD28 antibodies with
or without IL-27 (10 ng ml1) for 3 days. Flow cytometry
assays showed that the proportions of CD4þ IL-17þ cells
were reduced with IL-27 treatment, whereas the proportion of
CD4þ IFN-gþ T cells was similar between the two groups
(Figure 5a). IL-27 stimulation of CD4þ T cells of RA patients
increased the percentage of CD4þCD25þFoxp3þ Treg cells
under Th17-polarizing conditions (Figure 5b). The expression
of IL-27 in RA synovium increased compared with that of
osteoarthritis synovium (Figure 5c).
Figure 4 Reciprocal effects of interleukin (IL)-27 on the regulation of the T helper 17 (Th17) and regulatory T (Treg) lineage.
CD4þ T cells were isolated from human peripheral blood mononuclear cells (PBMCs) of healthy subjects and stimulated
with anti-CD3 plus anti-CD28 antibody stimulation with no cytokine added or in Th17-polarizing conditions in the presence
or absence of IL-27. (a) After 3 days, the cells were stained intracellularly with antibodies against IL-17 and interferon (IFN)-g
and analyzed by flow cytometry. A representative plot shows the frequencies of CD4þ IL-17þ cells and CD4þ IFN-gþ cells.
(b) In vitro differentiated CD4þCD25þFoxp3þ Treg cells under Th17 conditions in the presence or absence of IL-27
were identified by flow cytometric analysis. (c) The concentrations of IL-17, IFN-g and IL-10 in cultured supernatant from
(a) were analyzed by enzyme-linked immunosorbent assay. Foxp3, fluorescein isothiocyanate-labeled forkhead box P3; SSC,
side scatter channel.
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DISCUSSION
RA is a chronic inflammatory disorder that may lead to the
destruction of articular structure without effective anti-inflam-
matory therapies such as disease-modifying anti-rheumatic
drugs. Although the pathogenesis of RA remains uncertain,
broken Th17/Treg balance is considered to be involved in the
development as well as the progression of RA. Therefore, we
conducted this study to determine whether IL-27 has a role as
a reciprocal regulator in Th17 and Treg cells.
This study demonstrated the in vivo and in vitro effects of
IL-27 on the Th17 and Treg cell lineages in an RA animal
model and RA PBMCs. IL-27 downregulated Th17 differentia-
tion via RORgT and STAT3 inhibition and increased circulat-
ing Treg cells in vivo. Interestingly, the results show that IL-27
upregulated molecules involved in the suppressive function of
Tregs, such as PD-1, GITR and CTLA4, in Treg cells in the
spleens of CIA mice. Taken together, our study demonstrated
that IL-27 may overwhelmingly suppress the inflammation of
arthritis through the downregulation of Th17 cells via RORgT
and STAT3 and the upregulation of the Treg cell population, as
well as the augmentation of the suppressor activity of Treg cells
mainly by induction of CTLA-4. The effects of IL-27 on the
suppressor activity of Treg cells through the regulation of
costimulatory molecules have not been elucidated until now.
To the best of our knowledge, IL-27 has been consistently
reported to ameliorate arthritis severity and inflammation in
CIA models.9,22,23 In addition, in other animal models, a IL-27
deficiency exacerbates the disease severity of experimental
autoimmune encephalitis through the promotion of T-cell
proliferation and Th17 cell differentiation.24,25 Hall et al.26 also
identified the anti-inflammatory capacity of IL-27 in a mouse
model of toxoplasmosis. In their report, IL-27 could rescue
acute pathology by promoting Treg cells at the local
inflammation site.26 On the contrary, IL-27 acted in a
proinflammatory manner in the pathogenesis of psoriasis in
an animal model.27 In conclusion, the overall effects of IL-27
in vivo are dependent on the specific disease model.
The preferred differentiation of naive self-reactive T cells to
Th17 effector cells occurs via a particular cytokine milieu.28–30
The proinflammatory cytokines involved in Th17 development
were TGF-b,31 IL-2132 and IL-23.33 Th17 cells serve as a major
source of IL-17, and both human RA and mouse models
have shown that IL-17 is critical to joint inflammation and
destruction.34 The continuous administration of IL-17 induces
extensive inflammatory cell migration, bone erosion and
cartilage degradation.35,36 IL-17 also contributes to RA
chronicity through an antiapoptotic effect on resident RA
fibroblast-like synoviocytes. Conversely, blocking endogenous
IL-17 in a CIA model results in the suppression of arthritis.37
Currently, inspiring results were obtained in a phase I clinical
trial of an IL-17 targeting biologic agent in RA patients.38 Our
present study identified that in vitro administration of IL-27
reduced the IL-17 production that was associated with RORgT
expression.
The ability of Treg cells to regulate activated effector T cells
is also an important issue in autoimmune diseases in addition
Figure 5 Effects of interleukin (IL)-27 in rheumatoid arthritis
(RA) patients. (a) CD4þ T cells were isolated from human
peripheral blood mononuclear cells (PBMCs) isolated from RA
patients and were cultured in the presence of anti-CD3 plus
anti-CD28 stimulation with or without IL-27 for 3 days. The
proportion of CD4þ IL-17þ cells and CD4þ IFN-gþ cells was
measured by flow cytometry using intracellular staining for
IL-17 and interferon (IFN)-g. (b) The proportion of
CD4þCD25þFoxp3þ cells under T helper 17 (Th17)-polarizing
conditions in the presence or absence of IL-27 was determined
by flow cytometric analysis. (c) Immunohistochemical staining
was used to identify the expressions of IL-27 in RA
and osteoarthritis (OA) synovium (original magnification at
400). Foxp3, fluorescein isothiocyanate-labeled forkhead box
P3; SSC, side scatter channel.
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to an adequate number of Treg cells. The elimination or
abnormality of Treg cells can cause autoimmune diseases in
humans as well as animals.39 The depletion of Treg cells in CIA
exacerbated the arthritis severity.40 In patients with established
RA, the Treg cell population in peripheral blood and synovial
fluid has been shown to be comparable with that of the
controls.41,42 However, current studies have identified a defect
in Treg cell function in RA patients.43–46 Treg cells from RA
patients failed to inhibit the production of proinflammatory
cytokines by effector T cells.43
CTLA4, GITR and PD-1 on the surface of Treg cells are
considered to be involved in mediating the suppressive
functions of mainly cell-contact-dependent mechanisms.47–49
PD-1-deficient mice showed spontaneous development
of a lupus-like syndrome, including glomerulonephritis and
destructive arthritis, which demonstrated that PD-1 may be
involved in the prevention of autoimmune disease by
maintaining peripheral self-tolerance.50 Like the effect of PD-
1, CTLA-4 is required for the suppressive function of Tregs
during the development of those cells and during the effector
phase.51 Although the ligation of GITR molecules expressed on
Treg cells abrogates their suppressive activity following the
activation and proliferation on effector T cells, the expression
of GITR is upregulated upon activation compared with that on
naive Treg.21 In this study, the proportions of CTLA-4-, GITR-
and PD-1-expressing cells among the CD4þCD25þFoxp3þ
Tregs in spleens were augmented in IL-27-Fc-treated animals.
We postulate that this finding may suggest the augmented
suppressive capacity or activated stage of the Treg population
by IL-27-Fc treatment in a murine model of arthritis.
The current data have suggested that there are two subsets
of Treg cells, natural Treg (nTreg) cells and induced Treg
(iTreg) cells. The nTreg cells develop in the thymus and
undergo clonal expansion upon antigen exposure. The nTreg
cells can migrate to the periphery and suppress autoimmunity
through the inhibition of autoreactive T cells. However, iTreg
cells are generated in the periphery after antigen recognition by
CD4þCD25 T cells. Although the biology of iTreg cells is
still not well understood, they have been considered to be
involved in limiting the immune response in a cytokine (IL-10
and TGF-b)-mediated manner. In contrast, nTreg cells have an
immunosuppressive role via a contact-dependent mechanism
such as CTLA4. In this study, treatment with IL-27 caused an
increase in the IL-10 level in cultured murine CD4þ T cells,
although the TGF-b concentration did not change following
IL-27 treatment (data now shown). Interestingly, our study
identified that costimulatory molecules, especially in CTLA-4,
are upregulated in CD4þCD25þFoxp3þ Treg cells. Overall,
we carefully speculate that IL-27 contains an immunosuppres-
sive property in the CIA model through the nTreg population
rather than iTreg.
In summary, the results presented describe an anti-inflam-
matory effect of IL-27 in CIA, and IL-27 may mediate its
antiarthritic effects through inhibition of Th17 differentiation
via STAT3/RORgT and through a reciprocal induction of Treg
cells via Foxp3. In terms of suppressive function, upregulation
of costimulatory molecules on Treg cells, mainly CTLA-4, may
contribute to the antiarthritic effects of IL-27 shown in vivo.
Our study suggests that IL-27 has the potential to control
overwhelming inflammation in RA patients as a reciprocal
regulator of the Th17 and Treg cell lineages.
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